On May 4, 2016 the Food and Drug Administration (FDA) approved venetoclax (Venclexta®) for patients with chronic lymphocytic leukemia (CLL) whose tumors have a specific genetic alteration.
The accelerated approval is for patients with CLL whose tumor cells are missing a portion of chromosome 17, commonly referred to as a 17p deletion, and who have received at least one prior therapy for their cancer. Read more here.
No comments:
Post a Comment